Mysterious Vomiting Crisis Explodes—650%

Hazy,Kush,Medical,Marijuana,Flower.,Cannabis,Flower,Strain.,Indica,,Sativa,

Emergency rooms across America are overwhelmed with young adults experiencing a mysterious cannabis-linked vomiting syndrome that has surged 650% since 2016, and now the World Health Organization has officially recognized the condition—a development that reveals the hidden dangers of today’s dangerously potent marijuana products.

Quick Take

Cannabis Hyperemesis Syndrome (CHS) received official WHO diagnostic code R11.16 in October 2025, ending years of misdiagnosis and underreporting
Emergency room visits for CHS skyrocketed 650% from 2016 baseline, with cases remaining elevated post-pandemic
Modern cannabis products exceed 20% THC compared to 5% in the 1990s, with concentrated products reaching 90% THC—a potency explosion linked directly to rising CHS cases
Young adults aged 18-35 represent the highest-risk demographic, with addiction preventing many from quitting despite severe symptoms
The formal recognition enables systematic tracking and may drive regulatory action on product potency limits

The Hidden Crisis Behind Legalization

For years, emergency departments across America have witnessed a troubling pattern: young patients arriving with severe, intractable vomiting that traditional treatments couldn’t resolve. Many were initially misdiagnosed with food poisoning or gastroenteritis. The culprit? Chronic use of today’s extraordinarily potent cannabis products. Now, with the WHO’s October 2025 recognition of Cannabis Hyperemesis Syndrome and assignment of diagnostic code R11.16, the medical establishment has finally acknowledged what emergency physicians have known: this is a serious, growing public health crisis directly connected to the legalization movement’s failure to regulate product potency.

A 650% Surge in Emergency Room Cases

The numbers tell a stark story. A November 2025 JAMA Network Open study documented a staggering 650% increase in CHS-related emergency room visits from 2016 to pandemic peak levels, with cases remaining elevated through 2025. This isn’t a minor uptick—it represents a healthcare crisis unfolding in real time. The surge correlates directly with cannabis legalization efforts that expanded access to high-potency products and concentrated cannabis with THC levels exceeding 90%, a dramatic departure from the approximately 5% THC content typical of cannabis products in the 1990s.

Modern Cannabis: Not Your Parents’ Marijuana

The legalization industry has flooded markets with products of unprecedented potency. Contemporary recreational cannabis frequently exceeds 20% THC, while concentrated products regularly reach 90% or higher. This exponential increase in potency has fundamentally altered the risk profile for chronic users. The paradox is striking: while cannabis is marketed medically for treating nausea, chronic heavy use of today’s high-potency products triggers the opposite physiological response—severe, uncontrollable vomiting that can last hours or days. Patients report finding relief only through prolonged hot showers, a counterintuitive symptom pattern that delayed recognition of the condition for years.

Young Adults Bear the Burden

The demographic most affected by CHS is ages 18-35, suggesting younger users are either more vulnerable or more likely to use high-potency products. Addiction specialists report alarming increases in CHS among adolescents and young adults, with many patients unable to quit despite severe symptoms. The condition’s intermittent nature creates a dangerous misconception: patients who experience episodes weeks or months apart often believe the episodes were flukes rather than indicators of underlying susceptibility. Even after developing CHS, some users attempt to resume cannabis use, only to trigger immediate severe vomiting from even small amounts.

What CHS Actually Does to the Body

Cannabis Hyperemesis Syndrome manifests as severe nausea, repeated vomiting, and abdominal pain. The condition earned the clinical descriptor “scromiting”—screaming and vomiting simultaneously—reflecting the intensity of patient distress. Complications include dehydration, weight loss, and in rare cases, heart rhythm problems, seizures, kidney failure, and death. The condition’s severity demands repeated emergency department visits, creating substantial healthcare costs and disrupting patients’ lives. Yet many sufferers resist the CHS diagnosis, unable or unwilling to accept that their cannabis use is causing their suffering.

Why Official Recognition Matters

Prior to October 2025, CHS lacked formal recognition in diagnostic manuals, forcing physicians to use combination codes for nausea and vomiting plus cannabis use indicators. This fragmented approach prevented systematic tracking and obscured the true prevalence of the condition. The new diagnostic code R11.16 enables healthcare systems to generate accurate prevalence estimates for the first time, providing epidemiologists and public health officials with reliable data about disease burden and trends. This transparency may drive policy discussions about product potency regulation, including potential THC concentration limits or enhanced labeling requirements.

The Addiction Problem Nobody Wants to Discuss

Perhaps the most troubling aspect of the CHS crisis is that cannabis addiction prevents many sufferers from quitting despite debilitating symptoms. Research indicates that many people find it psychologically and physiologically difficult to discontinue cannabis use, even when facing severe health consequences. This addiction dynamic means that awareness campaigns alone may have limited behavioral impact. The condition’s treatment remains straightforward in principle—cannabis cessation—but extraordinarily difficult in practice for addicted users.

Mysterious marijuana-linked vomiting disorder gets official WHO code as ER cases jumphttps://t.co/iwiOEwOiLq

— Will Martin (@WillMartinJr) November 30, 2025

Policy Implications and Regulatory Pressure

The formal WHO recognition occurs within ongoing debates about cannabis legalization and regulation. Public health advocates will cite CHS prevalence data to argue for stricter potency regulations and age restrictions. The documented correlation between high-potency products and CHS prevalence provides evidence-based rationale for regulatory action that legalization proponents will struggle to counter. States and jurisdictions may implement THC concentration limits or require enhanced consumer education about potency-related risks—regulatory measures that the legalization industry has consistently resisted.